Bruce Yaffe, MD
General Practice · New York, NYNPI 1801962881
Payments from drug & device makers
What this record shows
This record is dominated by gifts: $19,057 of the $21,761 with a category attached, or 87.6%. Olympus America Inc. accounts for 87.6% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2019 at $20,233 and has fallen 99.0% since, to $209 in 2025. Among general practice clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 70 payments — averaging $310.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Olympus America Inc.$19K
- AbbVie$573
- Amarin Pharma, Inc.$416
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$378
- Sanofi-aventis U.S. LLC$353
- Gilead$268
- plus $717 from 11 others
What the payments were for
- Food & beverage$2,69812%
- Education$60%
- Gifts$19,05788%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Olympus America Inc. | 1 | $19,057 |
| AbbVie(2 entities) | 12 | $573 |
| Amarin Pharma, Inc. | 6 | $416 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $378 |
| Sanofi-aventis U.S. LLC | 4 | $353 |
| Gilead | 4 | $268 |
| Idorsia Pharmaceuticals US Inc | 7 | $158 |
| Amgen | 1 | $124 |
| GSK | 4 | $92 |
| CSL Behring | 1 | $86 |
| Lilly USA, LLC | 3 | $64 |
| Novo Nordisk | 3 | $60 |
| AstraZeneca | 2 | $41 |
| Inspire Medical Systems, Inc. | 1 | $29 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $26 |
| Genentech USA, Inc. | 1 | $18 |
| Merck | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,761 in reported general payments places this provider in the 95th percentile of 5,764 general practice providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 15 | $36,664 |
| EliquisApixaban | 16 | $25,853 |
| OzempicSemaglutide | 21 | $19,371 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 34 | $5,871 |
| Rosuvastatin Calcium | 290 | $3,763 |
| Carvedilol ErCarvedilol Phosphate | 12 | $3,037 |
| Atorvastatin Calcium | 127 | $1,606 |
| Ezetimibe | 54 | $1,468 |
| Zolpidem Tartrate | 119 | $1,203 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 28 | $1,141 |
| Olmesartan Medoxomil | 68 | $1,091 |
| Risedronate Sodium | 19 | $1,055 |
| Pantoprazole Sodium | 58 | $886 |
| Metoprolol Succinate | 63 | $867 |
| SynthroidLevothyroxine Sodium | 16 | $712 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $378 | $36,66415 claims |
| Novo NordiskOzempic | $60 | $19,37121 claims |
| AbbVieSynthroid | $573 | $71216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,764 general practice providers in New York.
Other general practice in New York
- Ronnie MyersNew York$464K
- Alejandra Gonzalez-DuarteNew York$183K
- Laila AkhlaghiNew York$52K
- Vezire SarakNew York$39K
- Yohan KimNew York$38K
- Christine SkordelesNew York$32K
- Jose GorisNew York$23K
- Joseph PantaleoNew York$14K
- Jeffrey ShapiroNew York$13K
- Michael KatayevNew York$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.